Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation

Launched by VANDERBILT UNIVERSITY MEDICAL CENTER · Oct 15, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating the relationship between early-onset atrial fibrillation (AF) and a specific heart problem called ventricular tachycardia (VT), which is a fast and potentially dangerous heart rhythm. Researchers aim to understand how common VT is in people with certain genetic changes (specifically in the TTN gene) compared to those without these changes. They will use specialized tests during a procedure called catheter-based ablation, which is done to treat AF, to study the heart's electrical activity and identify where VT may start.

To participate in this study, you must be at least 18 years old, have been diagnosed with AF before the age of 60, and be scheduled for an ablation procedure. It's important that you can provide written consent to join. Some people may not be eligible, such as those with certain heart conditions or previous heart surgeries. If you join, you can expect to undergo tests that will help doctors learn more about your heart's health and possibly improve treatment options for future patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults aged 18 and older
• • 2. Diagnosed with AF before age 60
• • 3. Scheduled for catheter-based AF ablation (de-novo or repeat)
• • 4. Able to provide written, informed consent
• • 5. P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.
• Exclusion Criteria:
• • 1. Diagnosed with a genetic CM or arrhythmia syndrome prior to AF
• • 2. VUS in 'possibly pathogenic' subgroup (control group only)
• • 3. Pacemaker or ICD
• • 4. Previous PVC or VT ablation
• • 5. LVEF \<20%
• • 6. Prosthetic mitral or aortic valve
• • 7. Contraindication to heparin
• • 8. Prior myocardial infarction.